Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma

1. Bartlett, N.L.
2. Assouline, S.
3. Giri, P.
4. Schuster, S.J.
5. Cheah, C.Y.
6. Matasar, M.
7. Gregory, G.P.
8. Yoon, D.H.
9. Shadman, M.
10. Fay, K.
11. Yoon, S.-S.
12. Panizo, C.
13. Flinn, I.
14. Johnston, A.
15. Bosch, F.
16. Sehn, L.H.
17. Wei, M.C.
18. Yin, S.
19. To, I.
20. Li, C.-C.
21. Huang, H.
22. Kwan, A.
23. Penuel, E.
24. Budde, L.E.